FDA Panel Finds Scant Clinical Utility In Nymox AlzheimAlert Diagnostic
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's immunology devices panel votes 5-2 against recommending approval for Nymox' AlzheimAlert at a July 15 meeting, after questioning whether the test would help primary care providers assess cognitively impaired patients.